Finance

Lists
ONCY:NASDAQ
Oncolytics Biotech Inc
$0.86
+2.03%
(+0.017) 1D
Aug 25, 11:29:28 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ONCY...
Open
$0.85
High
$0.87
Low
$0.84
Mkt. cap
110.22M
Avg. vol.
918.43K
Volume
330.76K
52-wk high
$1.51
52-wk low
$0.73
Beta
1.13
Shares outstanding
127.51M
No. of employees
29
Open
$0.85
High
$0.87
Low
$0.84
Mkt. cap
110.22M
Avg. vol.
918.43K
Volume
330.76K
52-wk high
$1.51
52-wk low
$0.73
Beta
1.13
Shares outstanding
127.51M
No. of employees
29
Profile
Oncolytics Biotech Inc. is a biotech company headquartered in San Diego, California, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Wikipedia
About Oncolytics Biotech Inc
CEO-
Employees29
Founded1998
HeadquartersCalgary, Alberta, Canada
SectorBiotechnology
Websiteoncolyticsbiotech.com
Analyst ratings
Based on 3 analysts giving stock ratings to ONCY in the past 3 months
Buy
Buy
2
Hold
1
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for ONCY in the last 3 months.
Highest
Current $0.86
$5.00 (+480.59%)
Average
$5.00 (+480.59%)
Lowest
$5.00 (+480.59%)
Analyst
Recommendation
Action
Price target
Projected
Date
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$5.00
+480.6%
08/20/2026
Boris Peaker
JonesTrading
Hold
Maintained
-
-
07/13/2026
Chad Messer
Lake Street
Buy
Maintained
$5.00
+480.6%
06/01/2026
Jason McCarthy
Maxim Group
Buy
Reiterated
$3.00
+248.4%
05/21/2026
Soumit Roy
JonesTrading
Hold
Maintained
-
-
04/06/2026
Previous reportsAll values in CAD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CAD
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
-
-
2.81M
7.52M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
-
2.90M
6.32M
Operating expense
-
-
5.71M
13.84M
Total operating expenses
-
-
5.71M
13.84M
Operating income
-
-
-5.71M
-13.84M
Other non operating income
-
-
-196.00K
-1.05M
EBT including unusual items
-
-
-6.08M
-14.65M
EBT excluding unusual items
-
-
-6.08M
-14.65M
Income tax expense
-
-
85.00K
-252.00K
Effective tax rate
-
-
-1.40%
1.72%
Other operating expenses
-
-
-
-
Net income
-
-
-6.16M
-14.40M
Net profit margin
-
-
-
-
Earnings per share
-0.10
-0.08
-0.07
-0.14
Interest and investment income
-
-
104.00K
100.00K
Interest expense
-
-
-
-
Net interest expenses
-
-
104.00K
100.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-5.68M
-13.82M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps